<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36422727</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>The level of homocysteine in amyotrophic lateral sclerosis: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1185</StartPage><EndPage>1192</EndPage><MedlinePgn>1185-1192</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06518-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the differences of the level of homocysteine (Hcy) between ALS patients and controls.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, EMBASE, OVID, and other databases were searched systematically up to October 2022 for relevant reports about the level of Hcy, folic acid, and vitamin B12 (VB12) among ALS patients. Two reviewers screened and selected the titles and abstracts of the studies independently during the database searches and performed full-text reviews and extracted available data. The MD (mean difference) and 95%CI (credibility interval) of the level of Hcy, folic acid, and VB12 between ALS group and control group were calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pooled results of nine studies including 812 ALS patients and 2632 controls showed that the MD in plasma levels of HCY between ALS patients and controls was 1.56 (95%CI:&#x2009;-&#x2009;0.07, 3.19) &#x3bc;mol/L with remarkable heterogeneity (I<sup>2</sup>&#x2009;=&#x2009;94%). The mean CSF levels of Hcy among ALS patients were significantly higher than that of controls (MD: 0.23, 95%CI: 0.21, 0.24&#xa0;&#x3bc;mol/L) with no significant heterogeneity (I<sup>2</sup>&#x2009;=&#x2009;0%). No significant difference in the plasma level of folic acid (MD:&#x2009;-&#x2009;0.52, 95%CI:&#x2009;-&#x2009;1.89, 0.84&#xa0;ng/mL) or VB12 (MD:&#x2009;-&#x2009;9.76, 95%CI:&#x2009;-&#x2009;83.41, 63.89) was found between ALS patients and controls.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There was no significant difference in the plasma level of Hcy, folic acid, or VB12 between ALS patients and controls. The CSF level of Hcy among ALS population was remarkably higher than that among controls. Vitamin supplements including folate and VB12 might be recommended to ALS patients with the complication of deficiencies.</AbstractText><CopyrightInformation>&#xa9; 2022. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4046-8439</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Beijing, 100730, China. hunan_pumch@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xubiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0LVT1QZ0BA</RegistryNumber><NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance></Chemical><Chemical><RegistryNumber>P6YC3EG204</RegistryNumber><NameOfSubstance UI="D014805">Vitamin B 12</NameOfSubstance></Chemical><Chemical><RegistryNumber>935E97BOY8</RegistryNumber><NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006710" MajorTopicYN="N">Homocysteine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014805" MajorTopicYN="N">Vitamin B 12</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Homocysteine</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36422727</ArticleId><ArticleId IdType="doi">10.1007/s10072-022-06518-6</ArticleId><ArticleId IdType="pii">10.1007/s10072-022-06518-6</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9(11):617&#x2013;628</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjaminsen E et al (2018) Amyotrophic lateral sclerosis in Nordland county, Norway, 2000&#x2013;2015: prevalence, incidence, and clinical features. Amyotroph Lateral Scler Frontotemporal Degener 19(7&#x2013;8):522&#x2013;527</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1513534</ArticleId><ArticleId IdType="pubmed">30265157</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari ME et al (2021) Prevalence of depression among amyotrophic lateral sclerosis (ALS) patients: a systematic review and meta-analysis. J Affect Disord 287:182&#x2013;190</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2021.03.015</ArticleId><ArticleId IdType="pubmed">33799036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun KY et al (2019) Epidemiology of ALS in Korea using nationwide big data. J Neurol Neurosurg Psychiatry 90(4):395&#x2013;403</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318974</ArticleId><ArticleId IdType="pubmed">30409890</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK (2019) Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 39(2):733&#x2013;748</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini T et al (2020) Clinical and lifestyle factors and risk of amyotrophic lateral sclerosis: a population-based case-control study. Int J Environ Res Public Health 17(3):857</Citation></Reference><Reference><Citation>Tjiattas L et al (2004) Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell 3(2):71&#x2013;76</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9728.2004.00086.x</ArticleId><ArticleId IdType="pubmed">15038821</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S, Cozzolino M, Carr&#xec; MT (2016) Old versus new mechanisms in the pathogenesis of ALS. Brain Pathol 26(2):276&#x2013;286</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12355</ArticleId><ArticleId IdType="pubmed">26779612</ArticleId><ArticleId IdType="pmc">8029354</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho KJ et al (1999) Reactive astrocytes express p53 in the spinal cord of transgenic mice expressing a human Cu/Zn SOD mutation. NeuroReport 10(18):3939&#x2013;3943</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199912160-00039</ArticleId><ArticleId IdType="pubmed">10716237</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y et al (2020) Elevated cerebrospinal fluid homocysteine is associated with blood-brain barrier disruption in amyotrophic lateral sclerosis patients. Neurol Sci 41(7):1865&#x2013;1872</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04292-x</ArticleId><ArticleId IdType="pubmed">32086685</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H et al (2017) Panel of oxidative stress and inflammatory biomarkers in ALS: a pilot study. Can J Neurol Sci 44(1):90&#x2013;95</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2016.284</ArticleId><ArticleId IdType="pubmed">27774920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellia C et al (2015) MTHFR C677T allelic variant is not associated with plasma and cerebrospinal fluid homocysteine in amyotrophic lateral sclerosis. Clin Chem Lab Med 53(3):e73&#x2013;e75</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2014-0465</ArticleId><ArticleId IdType="pubmed">25229416</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremolizzo L et al (2014) Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset. Amyotroph Lateral Scler Frontotemporal Degener 15(1&#x2013;2):98&#x2013;105</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.851247</ArticleId><ArticleId IdType="pubmed">24224837</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HL, Fan DS (2012) The relation between plasma homocysteine level and amyotrophic lateral sclerosis. Zhonghua Nei Ke Za Zhi 51(4):308&#x2013;310</Citation><ArticleIdList><ArticleId IdType="pubmed">22781953</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId><ArticleId IdType="pmc">2707599</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial &#x201c;Clinical limits of amyotrophic lateral sclerosis&#x201d; workshop contributors. J Neurol Sci 124:96&#x2013;107</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90191-0</ArticleId><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293&#x2013;299</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA et al (2011) Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 82(6):638&#x2013;642</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.236752</ArticleId><ArticleId IdType="pubmed">21471184</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentino F et al (2010) Elevated cerebrospinal fluid and plasma homocysteine levels in ALS. Eur J Neurol 17(1):84&#x2013;89</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02752.x</ArticleId><ArticleId IdType="pubmed">19659753</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin J et al (2010) Elevated levels of methylmalonate and homocysteine in Parkinson&#x2019;s disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. Dement Geriatr Cogn Disord 29(6):553&#x2013;559</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000314841</ArticleId><ArticleId IdType="pubmed">20606437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S et al (2008) Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology 70(3):222&#x2013;225</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000297193.53986.6f</ArticleId><ArticleId IdType="pubmed">18195267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukharaeva E et al (2015) Homocysteine aggravates ROS-induced depression of transmitter release from motor nerve terminals: potential mechanism of peripheral impairment in motor neuron diseases associated with hyperhomocysteinemia. Front Cell Neurosci 9:391</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00391</ArticleId><ArticleId IdType="pubmed">26500495</ArticleId><ArticleId IdType="pmc">4594498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Shea TB (2003) Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26(3):137&#x2013;146</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(03)00032-8</ArticleId><ArticleId IdType="pubmed">12591216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zieminska E et al (2006) Excitotoxic neuronal injury in acute homocysteine neurotoxicity: role of calcium and mitochondrial alterations. Neurochem Int 48(6&#x2013;7):491&#x2013;497</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2005.12.023</ArticleId><ArticleId IdType="pubmed">16513213</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura J et al (1999) Immunomodulation by vitamin B12: augmentation of CD8+ T lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment. Clin Exp Immunol 116(1):28&#x2013;32</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1999.00870.x</ArticleId><ArticleId IdType="pubmed">10209501</ArticleId><ArticleId IdType="pmc">1905232</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalabrino G, Veber D, Mutti E (2008) Experimental and clinical evidence of the role of cytokines and growth factors in the pathogenesis of acquired cobalamin-deficient leukoneuropathy. Brain Res Rev 59(1):42&#x2013;54</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2008.05.001</ArticleId><ArticleId IdType="pubmed">18538413</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemendinger RA, Armstrong EJ 3rd, Brooks BR (2011) Methyl Vitamin B12 but not methylfolate rescues a motor neuron-like cell line from homocysteine-mediated cell death. Toxicol Appl Pharmacol 251(3):217&#x2013;225</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2011.01.003</ArticleId><ArticleId IdType="pubmed">21237187</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X et al (2010) Decreased level of 5-methyltetrahydrofolate: a potential biomarker for pre-symptomatic amyotrophic lateral sclerosis. J Neurol Sci 293(1&#x2013;2):102&#x2013;105</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2010.02.024</ArticleId><ArticleId IdType="pubmed">20334883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP (2003) Methylation and acetylation in nervous system development and neurodegenerative disorders. Ageing Res Rev 2(3):329&#x2013;342</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1568-1637(03)00013-8</ArticleId><ArticleId IdType="pubmed">12726778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z et al (2008) ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11(4):420&#x2013;422</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId><ArticleId IdType="pmc">2895310</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S et al (2010) Reduction of circulating endothelial cells in peripheral blood of ALS patients. PLoS ONE 5(5):e10614</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010614</ArticleId><ArticleId IdType="pubmed">20485543</ArticleId><ArticleId IdType="pmc">2868893</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanger O et al (2003) DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 41(11):1392&#x2013;1403</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/CCLM.2003.214</ArticleId><ArticleId IdType="pubmed">14656016</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hnlein P et al (2011) The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is a possible risk factor for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12(2):136&#x2013;139</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.536985</ArticleId><ArticleId IdType="pubmed">21128869</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X et al (2008) Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice. Neuropharmacology 54(7):1112&#x2013;1119</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2008.02.020</ArticleId><ArticleId IdType="pubmed">18436268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S et al (2017) Methylcobalamin prevents mutant superoxide dismutase-1-induced motor neuron death in vitro. NeuroReport 28(2):101&#x2013;107</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0000000000000716</ArticleId><ArticleId IdType="pubmed">27922548</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl-Leszkowicz A, Keith G, Dirheimer G (1991) Effect of cobalamin derivatives on in vitro enzymatic DNA methylation: methylcobalamin can act as a methyl donor. Biochemistry 30(32):8045&#x2013;8051</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00246a024</ArticleId><ArticleId IdType="pubmed">1868079</ArticleId></ArticleIdList></Reference><Reference><Citation>Copped&#xe8; F (2014) The potential of epigenetic therapies in neurodegenerative diseases. Front Genet 5:220</Citation><ArticleIdList><ArticleId IdType="pubmed">25071843</ArticleId><ArticleId IdType="pmc">4094885</ArticleId></ArticleIdList></Reference><Reference><Citation>Green R et al (2017) Vitamin B(12) deficiency. Nat Rev Dis Primers 3:17040</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.40</ArticleId><ArticleId IdType="pubmed">28660890</ArticleId></ArticleIdList></Reference><Reference><Citation>Oki R et al (2022) Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol 79(6):575&#x2013;583</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.0901</ArticleId><ArticleId IdType="pubmed">35532908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji R et al (2019) Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study. J Neurol Neurosurg Psychiatry 90(4):451&#x2013;457</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319294</ArticleId><ArticleId IdType="pubmed">30636701</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>